黒色腫（メラノーマ）は、皮膚の最も表層である表皮にある皮膚の色素細胞であるメラノサイトの悪性新生物です。メラノサイトは神経堤組織の発生学上の派生物であり、そのため、神経堤の派生物であり、メラノサイトを含む体のあらゆる部位、すなわち皮膚、髄膜、粘膜、食道、眼の部位に黒色腫（メラノーマ）が発生する可能性があります。そのため、非皮膚型黒色腫（メラノーマ）は一般的に眼や粘膜に発生し、原発性黒色腫（メラノーマ）の4～5％を占めるに過ぎません。このレポートは、皮膚の黒色腫（メラノーマ）に焦点を当てています。黒色腫（メラノーマ）は、通常、皮膚上のほくろ（母斑）として現れ、非対称性、不規則な境界線、色の変化、直径が6ミリ以上であること、数週間から数カ月の間に外観が変化することが特徴です。これら5つの診断上の特徴は、頭文字をとってABCDEと呼ばれています。
GlobalData社の疫学者は、8主要市場では、黒色腫（メラノーマ）の診断された症例が2019年の190,771件から2029年には222,458件に増加し、年間成長率（AGR）が1.66％になると予測しています。アメリカは、予測期間を通じて黒色腫の症例数が最も多いでしょう。8主要市場で5年間に診断された黒色腫（メラノーマ）の有症症例も、2019年の794,304症例から2029年には947,373症例に増加し、AGRは1.93％になると予想されています。
目次
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Melanoma: Executive Summary
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Reports
3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Diagnosed Incident Cases of Melanoma
3.4.4 Diagnosed Incident Cases of Melanoma by Stage at Diagnosis
3.4.5 Mutations Among Diagnosed Incident Cases of Melanoma
3.4.6 Five-Year Diagnosed Prevalent Cases of Melanoma
3.5 Epidemiological Forecast for Melanoma, 2019-2029
3.5.1 Diagnosed Incident Cases of Melanoma
3.5.2 Sex-Specific Diagnosed Incident Cases of Melanoma
3.5.3 Age-Specific Diagnosed Incident Cases of Melanoma
3.5.4 Diagnosed Incident Cases of Melanoma by Stage at Diagnosis
3.5.5 Diagnosed Incident Cases of Melanoma by Mutations
3.5.6 Five-Year Diagnosed Prevalent Cases of Melanoma
3.6 Discussion
3.7 Epidemiological Forecast Insight
3.7.1 COVID-19 Impact
3.7.2 Limitations of the Analysis
3.7.3 Strengths of the Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About GlobalData
4.4 Contact Us
4.5 Disclaimer
List of Tables
Table 1: Summary of Newly Added Data Types and Countries
Table 2: Summary of Updated Data Types
Table 3: Risk Factors and Comorbidities for Melanoma
Table 4: 8MM, Diagnosed Incident Cases of Melanoma by Mutations, Ages ≥18 Years, Both Sexes, N, 2019
List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of Melanoma, Both Sexes, Ages ≥18 Years, 2019 and 2029
Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of Melanoma, Both Sexes, Ages ≥18 Years, 2019 and 2029
Figure 3: 8MM, Diagnosed Incidence of Melanoma, Men, Ages ≥18 Years, 2009-2029
Figure 4: 8MM, Diagnosed Incidence of Melanoma, Women, Ages ≥18 Years, 2009-2029
Figure 5: 8MM, Sources Used and Not Used to Forecast the Diagnosed Incident Cases of Melanoma
Figure 6: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Melanoma by Stage at Diagnosis
Figure 7: 8MM, Sources Used to Forecast the Diagnosed Incident Cases of Melanoma by Mutations
Figure 8: 8MM, Sources Used to Forecast the Five-Year Diagnosed Prevalent Cases of Melanoma
Figure 9: 8MM, Diagnosed Incident Cases of Melanoma, Both Sexes, Ages ≥18 Years, N, 2019
Figure 10: 8MM, Diagnosed Incident Cases of Melanoma, by Sex, Ages ≥18 Years, N, 2019
Figure 11: 8MM, Diagnosed Incident Cases of Melanoma by Age, Both Sexes, N, 2019
Figure 12: 8MM, Diagnosed Incident Cases of Melanoma by Stage at Diagnosis, Both Sexes, Ages ≥18 Years, N, 2019
Figure 13: 8MM, Five-Year Diagnosed Prevalent Cases of Melanoma, Ages ≥18 Years, Both Sexes, N, 2019
